Mitochondria based cell models that have yielded EMA and FDA approved products.

HTS and HCA  industry-validated screening platforms for drug discovery, and assessment of safety and efficacy of hits and leads. Assessment of mitochondrion function and behaviour within a living cell, maintaining existing mitochondrial interactions with multiplexed bio-assays.


Understanding the impact of a disease on  mitochondria is going one step closer to understanding the disease

Mitochondria Interacts With

All Cellular Components

1. Nucleolus

2. Nucleus

3. Ribosomes

4. Endocytosis & Exocytosis

5. RER

6. Golgi Apparatus

7. Cytoskeleton

8. SER

9. Lysosomes

10. Cytosol

11. Vacuoles

12. Centrosomes

13. Proteasomes

14. Cell Membrane

Given the central role played by mitochondria in cellular functioning, mitochondria driven patient-derived cell models to deliver a versatile platform from the perspective of :


Many diseases impact mitochondrial function and behavior, or concern mitochondrial metabolic pathways.

Examining molecules' ability to reverse these alterations at an early stage is required in managing you pipeline. 

Safety & Toxicity

Drugs, whatever their targets can also injure mitochondria since off-target effects of drugs may impact the mitochondrion functioning.


Mitochondria: A novel target for drug development

You can target mitochondria to try to reverse the effects a specific disease might have on them, or to trigger the apoptosis in diseased cells. 







Quantify effects of antiviral drugs on mtDNA content to limit HIV/HCV complications.

Mitochondrial bioenergetics and dynamics in cancer cell lines are associated with multi-drug resistance.

Determine your leads' impact on mitochondrial respiration, autophagy and/or dynamics, and their modulatory pathways.

Optimize leads and select disease-modifying drugs using patient-derived cell models.




Mitochondrial dysfunctions are crucial in metabolic diseases. Use one of our several experimental in vitro models available.

Select drugs targeting NASH through the restoration of mitochondrial function in the validated NASH-HepG2 model studying bioenergetics, redox status, ER stress, MAMs, membrane potential & more.

Mitochondria Can Derisk Diverse Pipelines At An Early Stage

Because previously undetected mitochondrial liabilities are the main cause of failure at the late clinical stage and post-marketing. 

Dykens & Will, DDT 12: 777-785, 2007 

See the DSEC validated Celesis toxicity profiler below.

Mechanisms of action of drugs can also be evaluated with ICDD's technologies for various indications.


Mitochondria profiling using live cells and cellular systems to understand your drug's impact or MOA

ICDD takes into account the mitochondrion and its environment: the cell. Indeed, all analysis of mitochondrial function and behavior is done inside a living cell, maintaining existing interactions, with integrated multiplexed bioassays.



The Mitostream® technology is a high content analysis (HCA) platform that examines mitochondrial behavior through phenotypic outcomes. It is the resultant of dynamical interactions of mitochondrial targets with targets in other cell compartments.

The bioassays are done in non-permeabilized primary living cells, and require no isolation of the mitochondria. They are customizable in pertinent cell models.

Enables Validation of:

  • Qualify and quantify cellular adaptability

  • Identify disease signatures from patient-derived cell models

  • Establish disease-modifying property of drugs

  • Profile toxicity potential

  • Establish organ-toxicity signatures

  • Anticipate clinical tolerance at the preclinical stage


Deploy the following ICDD models for your projects focusing on efficacy testing or toxicity screening.

The Mitosafe® technology is a high throughput screening (HTS) platform that examines 

mitochondrial function in functional bioassays in which multiplexed targets are assessed at the same time.

The bioassays are done in non-permeabilized primary living cells, and require no isolation of the mitochondria. They are customizable in pertinent cell models.

  • Drug mechanisms of action & pharmacological activity

  • Mitochondrial liabilities

  • Improve early de-selection of hits with mitochondrial liabilities

Enables Discovery of:




Toxicity Profiler


Assesses and quantifies Mitochondrial Behavior using the patented Mitostream

 technology & 48 descriptors in live cells.

  • AI algorithm based on trained reference datasets

  • Anticipate clinical tolerance at the preclinical stage




Bioenergetic Balance Screen

CDD's Bioenergetic Balance Screen (BBS), available in HTS/dose-response studies, helps you evaluate your compound's impact on β-oxidation, oxidative phosphorylation (OXPHOS) and the tricarboxylic (TCA) cycle.

The BBS+ package is the multiplexed and integrated measurements, in a same cell, of:

  • Oxygen consumption

  • ATP production

  • Glycolysis level

  • TCA cycle turning

  • Cell viability

  • Optimize tolerance prior to clinical evaluation

  • Assess the sensitivity of your cancer drugs

  • Compare your compound's activity in different cancer cell lines or tumor primary cultures

  • Evaluate how the glycolytic status of specific cancer cell lines modifies their response to your drug

  • Examine your compound's ability to modify tumor multi-drug resistance


Cancer Profiler

We offer a cancer profiler that combines an analysis of the Warburg effect through mitochondrial bioenergetics (BBS), of the Redox status and of mitochondrial fusion-fission dynamics to profile different cancer cells with regard to drug response.

A fully quantitative High Content Analysis (HCA) reading of mtDNA content to drug screening. You can also assess the impact of your drug on mtDNA content as a potential source of unwanted toxicity, as a drug-induced reduction in mtDNA content is associated with severe adverse drug reactions.

This package consists of the multiplexed and integrated measurements, in a same cell, of:

mtDNA Content

  • Mitochondrial DNA content

  • Mitochondrial mass

  • Mitochondrial biogenesis

  • Cell viability

  • Nucleus integrity and morphology, an apoptotic marker (optional)



Build a Custom Model For You.

Primary & iPSC-derviced Cell Models

  • AD et healthy cortical neurons

  • Sporadic PD, Lrrk2+ PD and healthy dopaminergic neurons

  • Hepatocytes

  • Cardiomyocytes

  • Glial & microglial cell models

ICDD has developed expertise in the development and validation of patient-derived cell models to increase results translatability. We favor primary cell models, but stem cell-derived pertinent cell models for specific diseases can also be obtained.


Validation of Mitochondrial behaviour and functioning at a genetic level

ICDD now delivers gene expression and miRNA profiles across all mitochondrial related pathways as a standard part of its services.


Experienced and trusted by industry

ICDD and its team have over 40 years of experience in mitochondrial biology, assay development & data modeling.

Dr. Nathalie Compagnone Ph.D.

Chief Scientific Officer & Founder, ICDD

Anubhav Anusha

Founder & CEO, GeneStore

In 2019, ICDD merged with GeneStore, a globally networked genomics company.

"This merger enables our clients to implement personalised care by matching functionally validated claims of their products to the unique genetic/biological needs of their end consumers.


Start A 


Discover How ICDD & The Mitchondria Can Assist You.


Our Locations


800 Avenue du Château de Jouques, 13420 Gémenos,
Provence-Alpes-Côte d'Azur
Telephone: +33 413 680 828



Suite 4, Building 47,
Dubai Healthcare City,
Dubai, United Arab Emirates
WTC - Torre 3 - Of. 474

Luis A. de Herrera

1248 C.P 11300, Montevideo, Uruguay


Suite 6f, Tower B4,
Spaze IT Park, Sohna Road
Gurugram, Haryana, 
© 2019 GeneStore. All rights reserved.
ICDD and GeneStore are trademarks of GeneStore France SAS.